Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced that they have launched their Illumina MiSeq Next-Gen sequencing services. Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider processing thousands of samples.
The Illumina MiSeq uses the same established reversible-terminator sequencing by synthesis chemistry as the HiSeq2000. Researchers have a wide range of sequencing read options ranging from 36 bp singleton to 150 bp paired-end reads. The system is capable of generating over 2 Gb data per run with a high percentage of bases over Q30. The high data yield and superior quality allows scientists to conduct a wide variety of sequencing applications including: highly multiplexed PCR amplicon sequencing, small genome sequencing and de novo sequencing, small RNA sequencing, targeted resequencing and 16S metagenomics.
“The addition of numerous Illumina MiSeqs adds another level of sequencing for our clients,” said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. “Our scientists have spent the last couple months validating sequencing runs and getting amazing results so we can deliver and work with multiple types of samples that fit on the MiSeq.”
“The MiSeq is a fully integrated sequencing platform enabling up to 2 GB of sequencing data using Illumina’s established and reliable TruSeq technology. The quick run time and high data yield make the system ideal for amplicon and targeted resequencing projects,” said Dr. Aaron Elliott, Director of Genomic Services.
Date: December 21, 2011
Source: Ambry Genetics